Comparative Pharmacology
Head-to-head clinical analysis: LEXAPRO versus LUVOX CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEXAPRO versus LUVOX CR.
LEXAPRO vs LUVOX CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin availability in the synaptic cleft by blocking serotonin reuptake transporters (SERT).
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
100-300 mg orally once daily at bedtime
None Documented
None Documented
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
The terminal elimination half-life is approximately 15-20 hours after single doses and 17-26 hours after multiple doses. This supports once-daily dosing, with steady-state achieved within 1-2 weeks.
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
Approximately 94% of a dose is excreted in urine, with less than 4% as unchanged drug. The remainder is eliminated in feces. Renal excretion of metabolites accounts for the majority of elimination.
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant